12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CERE-120: Phase IIb data

Top-line data from 51 patients with idiopathic PD in the double-blind Phase IIb portion of a U.S. Phase I/IIb trial showed that CERE-120 missed the primary endpoint of improving UPDRS Part III scores in the "off" state vs. sham surgery-controlled patients. Ceregene...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >